LOX and lung carcinoma: As the amino terminal LOX-PP domain of Pro-LOX has the ability to inhibit Ras-mediated transformation of NIH 3T3 cells [32] and H1299 lung cancer cells [25], its ability to reduce Blimp1 was next examined.